SCHEMBL3008583

SCHEMBL3008583

O=S(=O)(c1ccccc1C(F)(F)F)C1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.51
CTSS P25774 10/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
KDM1A O60341 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CRHBP P24387 1/20 0.43
MC4R P32245 1/20 0.43
CRHR2 Q13324 1/20 0.43
EIF4E P06730 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010123 0.93 CTSS (0.45) ARCTSSL3MBTL1SMN1; SMN2RAB9A
SCHEMBL3016817 0.93 CTSS (0.45) ARCTSSL3MBTL1SMN1; SMN2RAB9A
SCHEMBL3006941 0.90 KDM1A (0.55) CTSSL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL3015543 0.90 CTSS (0.48) CTSSL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL3016150 0.89 AR (0.56) ARCTSSSMN1; SMN2RAB9ANPC1
SCHEMBL3013619 0.88 CTSS (0.47) ARCTSSL3MBTL1SMN1; SMN2RAB9A
SCHEMBL3009173 0.88 MEN1 (0.52) ARCTSSL3MBTL1SMN1; SMN2RAB9A
SCHEMBL3010184 0.87 CTSS (0.47) ARCTSSL3MBTL1SMN1; SMN2RAB9A
SCHEMBL3016913 0.86 AR (0.52) ARL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL3010049 0.86 AR (0.53) ARCTSSSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885CTSS 106/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.